eligibility_summary
Key eligibility: Adults (≥18) with path‑confirmed recurrent glioblastoma after standard therapy, KPS≥60, life expectancy ≥3 mo, prior toxicities ≤G1, adequate organ/cardiac function (LVEF≥50%) and labs, neg pregnancy test/contraception. Exclude: recent anticancer therapy, CNS bleed/infarct ≤6 mo, significant CV/cerebrovascular dz, arrhythmias/QT, autoimmune disease, other active cancer, uncontrolled HTN/diabetes, ILD/severe lung disease, antibody allergy, prior transplant, active HIV/TB/HBV/HCV or recent infection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: BL-B01D1 (iza-bren, izalontamab brengitecan, BMS-986507), an antibody–drug conjugate (ADC) given IV every 3 weeks. Mechanism of action: a monoclonal antibody binds a tumor-associated cell-surface antigen (specific antigen not specified in this listing), is internalized, and releases a brengitecan topoisomerase I inhibitor payload in tumor cells, causing DNA damage and apoptosis, Fc-mediated immune effector functions (e.g., ADCC/CDC) may also contribute. Targeted cells/pathways: antigen-expressing glioblastoma cells, DNA replication/repair via Topoisomerase I, leading to cell-cycle arrest and tumor cell death. Phase: II, single-arm, recurrent glioblastoma.